Israeli Pharmaceutical Industry: Teva and Generic Drugs
Trace Teva’s growth and see how Israeli research, regulation and manufacturing contribute to pharmaceutical exports.
Category pages
- From S.L.E. to Teva: The Industry's Early HistoryTeva traces its origins to S.L.E., a Jerusalem medicine distributor founded in 1901. The modern Teva Pharmaceutical Industries formed in 1976 when Teva, Assia and Zori merged under Eli Hurvitz’s leadership.
- Eli Hurvitz and Teva's Global ExpansionEli Hurvitz led Teva through decades of international growth. Acquisitions of IVAX, Barr and ratiopharm gave the Israeli company broader reach in the Americas and Europe and expanded its generic medicine business.
- Teva's API Business and the Global Drug SupplyTeva’s API business develops and manufactures active ingredients for medicines. Teva announced a planned divestment in 2024; its 2024 annual report classified the business as held for sale at year end.
- Copaxone: Weizmann Research to Multiple Sclerosis TreatmentWeizmann scientists Michael Sela, Ruth Arnon and Dvora Teitelbaum developed the research behind glatiramer acetate. Teva developed Copaxone, which received its initial U.S. approval in 1996 for relapsing forms of multiple sclerosis.
- Azilect: Technion Research and Clinical DevelopmentTechnion researchers John Finberg and Moussa Youdim developed rasagiline with Teva, later marketed as Azilect. In the 2009 ADAGIO trial, the primary delayed-start criteria were met at 1 mg daily but not at 2 mg.
- Drug Approval and Manufacturing in IsraelIsrael’s Health Ministry enforces good manufacturing practice requirements and inspects medicine production sites. FDA records document inspections at Teva’s Kfar Saba facility; an inspection evaluates a site, while product approval applies to a specific drug.
- Israeli Pharmaceutical Research, Manufacturing and ExportsIsraeli drug development can connect university research to company development, regulated manufacturing and export markets. Israel’s Central Bureau of Statistics recorded $3.7445 billion in 2022 exports for conventional and homeopathic pharmaceutical products.